vs

Side-by-side financial comparison of COMPUGEN LTD (CGEN) and ClearSign Technologies Corp (CLIR). Click either name above to swap in a different company.

ClearSign Technologies Corp is the larger business by last-quarter revenue ($3.7M vs $3.5M, roughly 1.0× COMPUGEN LTD). ClearSign Technologies Corp runs the higher net margin — -8.5% vs -410.1%, a 401.7% gap on every dollar of revenue. On growth, ClearSign Technologies Corp posted the faster year-over-year revenue change (522.2% vs -61.8%).

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big compan...

ClearSign Technologies Corporation (ClearSign) is a United States-based company that develops emission-control technology.

CGEN vs CLIR — Head-to-Head

Bigger by revenue
CLIR
CLIR
1.0× larger
CLIR
$3.7M
$3.5M
CGEN
Growing faster (revenue YoY)
CLIR
CLIR
+584.0% gap
CLIR
522.2%
-61.8%
CGEN
Higher net margin
CLIR
CLIR
401.7% more per $
CLIR
-8.5%
-410.1%
CGEN

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CGEN
CGEN
CLIR
CLIR
Revenue
$3.5M
$3.7M
Net Profit
$-14.5M
$-311.0K
Gross Margin
21.9%
Operating Margin
-475.1%
-22.5%
Net Margin
-410.1%
-8.5%
Revenue YoY
-61.8%
522.2%
Net Profit YoY
-54.7%
73.3%
EPS (diluted)
$-0.16
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CGEN
CGEN
CLIR
CLIR
Q4 25
$3.7M
Q3 25
$1.0M
Q2 25
$3.5M
$133.0K
Q1 25
$401.0K
Q4 24
$590.0K
Q3 24
$1.9M
Q2 24
$9.3M
$45.0K
Q1 24
$2.6M
$1.1M
Net Profit
CGEN
CGEN
CLIR
CLIR
Q4 25
$-311.0K
Q3 25
$-1.4M
Q2 25
$-14.5M
$-1.7M
Q1 25
$-2.1M
Q4 24
$-1.2M
Q3 24
$-1.2M
Q2 24
$-9.4M
$-1.9M
Q1 24
$7.3M
$-1.1M
Gross Margin
CGEN
CGEN
CLIR
CLIR
Q4 25
21.9%
Q3 25
35.8%
Q2 25
41.4%
Q1 25
48.9%
Q4 24
14.9%
Q3 24
29.6%
Q2 24
60.5%
93.3%
Q1 24
17.9%
39.7%
Operating Margin
CGEN
CGEN
CLIR
CLIR
Q4 25
-22.5%
Q3 25
-170.1%
Q2 25
-475.1%
-1382.0%
Q1 25
-562.8%
Q4 24
-282.4%
Q3 24
-77.1%
Q2 24
-128.5%
-4748.9%
Q1 24
-113.6%
Net Margin
CGEN
CGEN
CLIR
CLIR
Q4 25
-8.5%
Q3 25
-138.9%
Q2 25
-410.1%
-1263.2%
Q1 25
-517.7%
Q4 24
-197.3%
Q3 24
-62.1%
Q2 24
-101.4%
-4160.0%
Q1 24
284.0%
-100.5%
EPS (diluted)
CGEN
CGEN
CLIR
CLIR
Q4 25
$-0.06
Q3 25
$-0.26
Q2 25
$-0.16
$-0.30
Q1 25
$-0.37
Q4 24
$-0.18
Q3 24
$-0.20
Q2 24
$-0.10
$-0.40
Q1 24
$89505618.00
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CGEN
CGEN
CLIR
CLIR
Cash + ST InvestmentsLiquidity on hand
$35.3M
$9.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$50.3M
$9.5M
Total Assets
$106.5M
$12.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CGEN
CGEN
CLIR
CLIR
Q4 25
$9.2M
Q3 25
$10.5M
Q2 25
$35.3M
$12.3M
Q1 25
$12.9M
Q4 24
$14.0M
Q3 24
$14.5M
Q2 24
$44.6M
$16.0M
Q1 24
$39.3M
$4.6M
Stockholders' Equity
CGEN
CGEN
CLIR
CLIR
Q4 25
$9.5M
Q3 25
$9.1M
Q2 25
$50.3M
$10.4M
Q1 25
$12.0M
Q4 24
$13.8M
Q3 24
$14.8M
Q2 24
$58.3M
$15.9M
Q1 24
$65.6M
$4.5M
Total Assets
CGEN
CGEN
CLIR
CLIR
Q4 25
$12.2M
Q3 25
$12.7M
Q2 25
$106.5M
$14.2M
Q1 25
$14.5M
Q4 24
$16.3M
Q3 24
$17.1M
Q2 24
$110.2M
$17.8M
Q1 24
$121.3M
$6.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CGEN
CGEN
CLIR
CLIR
Operating Cash FlowLast quarter
$-18.6M
$-1.3M
Free Cash FlowOCF − Capex
$-18.8M
FCF MarginFCF / Revenue
-530.8%
Capex IntensityCapex / Revenue
6.5%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CGEN
CGEN
CLIR
CLIR
Q4 25
$-1.3M
Q3 25
$-1.8M
Q2 25
$-18.6M
$-511.0K
Q1 25
$-1.1M
Q4 24
$-415.0K
Q3 24
$-1.4M
Q2 24
$39.7M
$-1.5M
Q1 24
$-1.0M
Free Cash Flow
CGEN
CGEN
CLIR
CLIR
Q4 25
Q3 25
Q2 25
$-18.8M
Q1 25
$-1.1M
Q4 24
Q3 24
Q2 24
$39.7M
Q1 24
FCF Margin
CGEN
CGEN
CLIR
CLIR
Q4 25
Q3 25
Q2 25
-530.8%
Q1 25
-278.1%
Q4 24
Q3 24
Q2 24
428.3%
Q1 24
Capex Intensity
CGEN
CGEN
CLIR
CLIR
Q4 25
0.0%
Q3 25
0.0%
Q2 25
6.5%
0.0%
Q1 25
1.0%
Q4 24
Q3 24
0.0%
Q2 24
0.4%
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons